Zomedica pharmaceuticals corp. (ZOM)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Expenses:
Research and development

789

962

1,061

7,531

6,551

630

2,534

600

1,165

465

504

616

General and administrative

1,557

1,404

921

3,231

1,278

834

1,248

1,160

1,019

1,350

748

827

Professional fees

306

279

211

739

533

293

336

371

351

246

314

381

Amortization - right-of-use asset

127

127

127

127

-

-

-

-

-

-

-

-

Accumulated Amortization, Amortization

0

0

0

0

0

0

0

0

0

0

0

0

Depreciation

76

70

68

62

53

86

27

36

23

22

22

20

Loss from operations

-2,857

-2,844

-2,391

-11,691

-8,416

-1,845

-4,147

-2,169

-2,561

-2,086

-1,590

-1,846

Loss on fixed asets

-

-

-1

-

-

-69

-

-

-

-

-

-

Interest expense

0

0

12

6

-

-

-

-

-

-

-

-

Gain on settlement of liabilities

0

0

0

19

-

-

-

-

0

0

0

5

Loss on sale of equipment

-

-

-

-

-

-

-

-

-

0

-

-

Foreign exchange gain

0

-1

0

1

-5

4

3

-1

-2

5

2

8

Loss before income taxes

-2,857

-2,845

-2,404

-11,676

-8,421

-1,910

-4,144

-2,171

-2,563

-2,080

-1,588

-1,832

Income tax expense

-

-

-

-

-

-

-

-

-

0

0

0

Net loss and comprehensive loss

-2,857

-2,845

-2,404

-11,676

-8,421

-1,910

-4,144

-2,171

-2,563

-2,080

-1,588

-1,832

Weighted average number of common shares - basic and diluted (in shares)

108,251

108,038

108,038

100,864

96,201

94,514

92,527

90,517

89,260

88,844

87,077

84,418

Loss per share - basic and diluted (in dollars per share)

-0.02

-0.03

-0.02

-0.12

-0.10

-0.02

-0.04

-0.02

-0.03

-0.02

-0.02

-0.02